Clinical trials: Gastrointestinal Lesions
- Condition Gastrointestinal Lesions
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Colo-rectal Cancer
Safety,Usability and Compliance of Using C-Scan System for Providing Information on Colonic Polypoid Lesions and Masses
Protocol Title: Evaluation of safety, usability and subject compliance while using Check- Cap's C-Scan System for providing structural information on colonic polypoid lesions and masses Study Design: Prospective, Multi-center…
- Trial name
- C-Scan (NCT03735407)
- Testing
- C-Scan procedure
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Check-Cap Ltd.
Gastrointestinal Lesions
Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo
This is a double-blind, placebo-controlled, randomized, parallel trial to evaluate if rebamipide reduces the number of gastric events caused by naproxen.
- Trial name
- NCT02632812
- Testing
- Rebamipide effervescent granules, Naproxen tablet
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Biolab Sanus Farmaceutica
Colorectal Cancer
CB-17-08 Augmented Endoscopy System for Mucosal Lesion Detection During Colonoscopy for Colon Rectal Cancer.
The aim of this study is to assess the performance of the CB-17-08 to help endoscopists find potential mucosal polyps during the colonoscopy procedure, without significant noise disturbing the endoscopist attention, nor negative…
- Trial name
- NCT03954548
- Testing
- CB-17-08 CADe
- Where
- 10 sites in United States, Italy and 1 more
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Cosmo Artificial Intelligence-AI Ltd
Screening for Colon Cancer, Blood Samples
Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection
The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas…
- Conditions
- Screening for Colon Cancer, Blood Samples, Survey and Questionnaire, Colorectal Carcinoma
- Trial name
- MS-Prevecol (NCT06703632)
- Testing
- blood sampling, Survey using a questionnaire.
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 4,538 people, healthy volunteers welcome
- Sponsor
- ADVANCED MARKER DISCOVERY S.L.
Gastric Lesion, Gastric Precancerous Condition
Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer
The goal of this study is to characterize and validate a signature of circulating biomarkers in plasma, associated with the presence of gastric preneoplasia in patients with preexisting gastric lesion compared with a control…
- Conditions
- Gastric Lesion, Gastric Precancerous Condition, Gastric Cancer
- Trial name
- PREGASIGN#1 (NCT05854368)
- Testing
- Additional blood collection as part of a blood sampling performed during routine care or specific for the research if not part of routine care., Blood collection
- Where
- 8 sites in France
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Bowel Diseases, Inflammatory
Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole
To evaluate the small bowel lesion pattern associated with celecoxib alone versus ibuprofen plus omeprazole
- Trial name
- NCT00640809
- Testing
- Celecoxib, Ibuprofen plus Omeprazole
- Where
- 12 sites in United States
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Colon Cancer, Rectal Cancer
Prevention of Colorectal Cancer Through Multiomics Blood Testing
The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a…
- Conditions
- Colon Cancer, Rectal Cancer, Colon Neoplasm, Colon Diseases
- Trial name
- PREEMPT CRC (NCT04369053)
- Testing
- Freenome test
- Where
- 148 sites in United States, Canada
- Volunteers
- 48,995 people, healthy volunteers welcome
- Sponsor
- Freenome Holdings Inc.
Colorectal Cancer, Advanced Adenocarcinoma
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.
- Trial name
- NCT06059963
- Testing
- Signal-C™
- Where
- United States
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Universal Diagnostics